These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38836510)

  • 21. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
    Shin KH; Choi HD
    Int J Clin Pharmacol Ther; 2024 Jun; 62(6):250-258. PubMed ID: 38529927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study.
    van Bruggen FH; Zuidema SU; Luijendijk HJ
    BMC Med Res Methodol; 2024 Jun; 24(1):137. PubMed ID: 38909176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.
    Leiter LA; Tinahones FJ; Karalis DG; Bujas-Bobanovic M; Letierce A; Mandel J; Samuel R; Jones PH
    Diabet Med; 2018 Dec; 35(12):1742-1751. PubMed ID: 30183102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
    Ray KK; Leiter LA; Müller-Wieland D; Cariou B; Colhoun HM; Henry RR; Tinahones FJ; Bujas-Bobanovic M; Domenger C; Letierce A; Samuel R; Del Prato S
    Diabetes Obes Metab; 2018 Jun; 20(6):1479-1489. PubMed ID: 29436756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials.
    Dai H; Zhu Y; Chen Z; Yan R; Liu J; He Z; Zhang L; Zhang F; Yan S
    Endokrynol Pol; 2023; 74(3):234-242. PubMed ID: 37335067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
    Goodman SG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Harrington RA; Jukema JW; White HD; Zeiher AM; Manvelian G; Pordy R; Poulouin Y; Stipek W; Garon G; Schwartz GG;
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):342-352. PubMed ID: 38658193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
    N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Carugo S; Sirtori CR; Corsini A; Tokgozoglu L; Ruscica M
    Curr Atheroscler Rep; 2022 Dec; 24(12):995-1004. PubMed ID: 36383291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.
    Hollstein T; Kassner U; Grenkowitz T; Schumann F; Bobbert T; Steinhagen-Thiessen E
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):83-92. PubMed ID: 32514867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
    O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
    Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
    Marston NA; Gurmu Y; Melloni GEM; Bonaca M; Gencer B; Sever PS; Pedersen TR; Keech AC; Roselli C; Lubitz SA; Ellinor PT; O'Donoghue ML; Giugliano RP; Ruff CT; Sabatine MS
    Circulation; 2020 May; 141(20):1600-1607. PubMed ID: 32223429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
    Karatasakis A; Danek BA; Karacsonyi J; Rangan BV; Roesle MK; Knickelbine T; Miedema MD; Khalili H; Ahmad Z; Abdullah S; Banerjee S; Brilakis ES
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29223954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.
    Harvey PD; Sabbagh MN; Harrison JE; Ginsberg HN; Chapman MJ; Manvelian G; Moryusef A; Mandel J; Farnier M
    Eur Heart J; 2018 Feb; 39(5):374-381. PubMed ID: 29186504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors.
    Seijas-Amigo J; Gayoso-Rey M; Mauriz-Montero MJ; Suarez-Artime P; Casas-Martinez A; Dominguez-Guerra M; Gonzalez-Freire L; Estany-Gestal A; Codero-Fort A; Rodriguez-Mañero M; Gonzalez-Juanatey JR;
    Clin Investig Arterioscler; 2022; 34(5):245-252. PubMed ID: 35287972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.